• Customer Care
  • (888) 123-4567

Scientist — Molecular Biology & Assay Development

 

Job description:

We are seeking a versatile and motivated Junior Scientist with hands-on experience in molecular biology, assay development, and quality control. This role offers an opportunity to work across R&D, process development, and analytical testing in support of novel live biotherapeutic and biologic drug programs.

Key Responsibilities:

· Perform molecular biology techniques such as DNA/RNA extraction, cloning, PCR, and qPCR.

· Develop and optimize cell-based and biochemical assays for product characterization, including ELISA, Western blot, flow cytometry.

· Support analytical and QC testing for preclinical and clinical materials.

· Maintain detailed experimental records and prepare technical reports.

· Collaborate cross-functionally with R&D, Process Development, and QA/QC teams.

· Assist in troubleshooting, data interpretation, and continuous process improvement.

Qualifications & Requirements:

· BS or MS in Molecular Biology, Biochemistry, Microbiology, or a related field.

· 1–3 years of hands-on laboratory experience (academic or industry).

· Experience with molecular biology techniques and basic assay development.

· Strong analytical, organizational, and communication skills.

· Ability to work independently and as part of a collaborative team.

Preferred Experience:

· Experience with microbial cell culture.

· Exposure to assay qualification or validation in a regulated environment.

· Familiarity with QC testing and GMP documentation practices.

 

What We Offer:

· Competitive salary and benefits package.

· Hands-on experience with advanced therapeutic technologies.

· Opportunity to contribute to groundbreaking therapies in a collaborative, science-driven company.

 

Job Type: Contract

Benefits:

· 401(k) matching

· Dental insurance

· Health insurance

· Health savings account

· Vision insurance

Work Location: In person

 

Please email your CV or resume to: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About Rise Therapeutics

Rise Therapeutics is an emerging, privately held company located in Rockville, Maryland , which leverages its expertise in synthetic biology and immunological drug development to create novel cellular-based immune therapies. With a strong emphasis on product development and its internal clinical GMP manufacturing infrastructure, Rise is focused on developing immunological-based biological medicines using a unique and proprietary oral biologics delivery platform. Our drug development focus is driven by new microbiome-related discoveries enabling development of targeted, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity, cancer, and infection. In the context of its expertise in synthetic biology medicine, proprietary TPX oral drug delivery platform, and clinical GMP manufacturing capabilities, Rise is creating and rapidly advancing life changing cellular-based medicines to the market. For more information, go to www.risetherapeutics.com.

Our News

Rockville, MD — September 23, 2025— Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, today announced it will be initiating clinical evaluation of R-2487 in SjD.

Rockville, MD., April 7, 2025 -- Rise Therapeutics, a biopharmaceutical company developing precision immunotherapies, today announced that it will report its first clinical results from the completed dose escalation segment of its R-3750 Phase 1 clinical trial in ulcerative colitis at the upcoming DDW conference in San Diego on May 6th.

Rockville, Maryland, January 13, 2025 – Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780. This is Rise Therapeutics’ fourth clinical program to enter patient clinical testing. For separate products, other clinical studies are ongoing for the treatment of ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.